Abstract
Treatment for multiple myeloma (MM) is unsatisfactory. Although the combination of melphalan and prednisolone given for four days every six weeks is capable of producing responses in about 60% of patients,no-one is cured and median survivals are about three years. Moreover there has been no significant improval in survival over the past 30 years [1]. High dose melphalan (HDM) [2] produces complete remission rates of 27% and a median duration of remission of 19 months.A complete remission in this context means no detectable paraprotein in serum or urine. MM is always detectable by more sensitive techniques. Nevertheless, this is the maximum therapy without bone marrow support.
This work was supported by the Leukemia Research Fund and Tenovus.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Sporn JR, Mclntyre OR. Chemotherapy of previous untreated multiple myeloma patients: An analysis of recent treatment results Semin Oncol 1986; 13: 318–25.
Selby PJ, McElwain TJ, Nandi Ac, et al. Multiple myeloma treated with high dose intravenous melphalan. Br J Haematol 1987;66:55–62.
Wolff SN, McCurley TL, Gianmore L. High dose chemoradiotherapy with syngeneic bone marrow transplantation for multiple myeloma. Amer J Haematol 1987; 26:191–8.
Gahrton G, Tura S, Flesch M, et al. Bone marrow transplantion in multiple myeloma: Report from the European Co-operative Group for Bone Marrow Transplantation. Blood 1987;69:1262–4.
Barlogie B, Alexanian R, Dicke K. High dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma. Blood 1987;70:869–72.
Bell AJ, Hamblin TJ, Oscier DG. Circulating stem cell autografts. Bone Marrow Transplant 1986;1:103–10.
Mellstedt H, Holm G, Petterson D, Peert D. Idiotype bearing lymphoid cells in plasma cell neoplasia. Clinics in Haematol 1982;11:65–86.
To LB, Dyson PG, Juttner CA. Cell-dose effect in circulating stem-cell autografting. Lancet 1986;ii:404–5.
Lockhorst HM, Boom SE, Bast BJEG. A novel type of proliferating lym- phoplasmacytoid cell with characteristic spotted immunofluorescence pattern. J Clin Invest 1987;79:1401–11.
Fermand J-P, Levy Y, Gerota J, et al. Treatment of aggressive multiple myeloma by high-dose chemotherapy and total body irradiation followed by blood stem cells autologous graft. Blood 1989;73:20–3.
Reiffers J, Marit G, Boiron JM. Autologous stem cell transplantation in high risk multiple myeloma (letter). Br J Haematol 1989;72:296–7.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1991 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Hamblin, T.J., Bell, A.J., Cusak, R., Figes, A., North, J., Stevenson, F.K. (1991). Peripheral Blood Stem Cell Transplants in Myeloma. In: Sibinga, C.T.S., Kater, L. (eds) Advances in haemapheresis. Developments in Hematology and Immunology, vol 25. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-3904-9_16
Download citation
DOI: https://doi.org/10.1007/978-1-4615-3904-9_16
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-6742-0
Online ISBN: 978-1-4615-3904-9
eBook Packages: Springer Book Archive